[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363465-105":59,"doc-detail-363465-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cell-cycle-targeted-cancer-therapy-clinical-advances-biological-gaps-and-the-emergence-of-selective-cdk4-inhibitors","Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors","","Cyclin-dependent kinase (CDK) 4/6 inhibitors have transformed treatment for hormone receptor (HR)-positive breast cancer and validated cell-cycle regulation as a therapeutic target in oncology. Despite strong biological rationale, clinical progress beyond this context has been slower than expected. This review analyzes key knowledge gaps in CDK4/6–cyclin D signaling and its context-dependent roles in tumor initiation and growth. It surveys clinical achievements and limitations, then outlines next-generation highly selective CDK4 inhibitor strategies to broaden and refine use while addressing resistance and toxicities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cell-cycle-targeted-cancer-therapy-clinical-advances-biological-gaps-and-the-emergence-of-selective-cdk4-inhibitors/363465/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cell-cycle-targeted-cancer-therapy-clinical-advances-biological-gaps-and-the-emergence-of-selective-cdk4-inhibitors/363465.png","ImageObject",300,407,{"name":92,"@type":93},"Grenda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological pathway does the review focus on?","Question",{"text":112,"@type":113},"The review centers on CDK4/6–cyclin D signaling as a key link between extracellular mitogenic cues and cell-cycle control, and as a pathway frequently dysregulated in malignancy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why has CDK4/6 inhibition expanded more slowly beyond HR-positive breast cancer?",{"text":117,"@type":113},"Broader use is limited by intrinsic or acquired resistance, restricted efficacy in certain tumor contexts, and dose-limiting hematologic toxicities.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the goal behind developing next-generation selective CDK4 inhibitors?",{"text":121,"@type":113},"The intent is to overcome existing challenges by improving selectivity, refining the therapeutic window, and maintaining effective suppression of the CDK4 pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363465,1790925653,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Safaroghli-azar etal. Journal of Hematology & Oncology (2026) 19:31 [https://doi.org/10.1186/s13045-026-01794-7](https://doi.org/10.1186/s13045-026-01794-7)  \nJournal of Hematology & Oncology  \nREVIEW Open Access  \nCell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors  \nAva Safaroghli-azar1, Laychiluh B. Mekonnen 1, Jimma Lenjisa1, Robert Milne1 and Shudong Wang1*  \nAbstract  \nCyclin-dependent kinase (CDK) 4/6 inhibitors have reshaped the therapeutic landscape for hormone receptor (HR)-positive breast cancer and firmly established cell-cycle regulation as a viable target in oncology. Yet, despite strong biological rationale, their clinical impact outside this setting has expanded more slowly than anticipated. This review dissects key gaps in our understanding of CDK4/6–cyclin D signalling and its context-dependent roles in tumourigenesis. We begin by the outlining molecular biology of CDK4, CDK6, and D-type cyclins, highlighting their contributions to malignant proliferation and lineage-specific vulnerabilities. We then examine the therapeutic landscape defined by CDK4/6 inhibition, summarising key clinical successes as well as ongoing limitations, including resistance, restricted therapeutic applicability, and haematologic toxicities. Finally, we discuss emerging strategies to overcome these challenges, with particular emphasis on the development of next-generation, highly selective CDK4 inhibitors that may refine and extend the clinical utility of cell-cycle-targeted therapy.  \nKeywords Cell-cycle-targeted therapy, CDK4/6 inhibitors, CDK4-seletive inhibitors, Tumourigenesis, Drug resistance, Haematologic toxicity  \nIntroduction  \nIn the late 1980s, cyclin-dependent kinases (CDKs) and their regulatory cyclins were identified as central coordinators of cell division and transcriptional control [1]. CDKs comprise a family of serine/threonine kinases (CDK1–20) characterised by a bilobed structure: an amino-terminal N-lobe that mediates ATP binding and substrate recognition, and a carboxy-terminal C-lobe containing the phosphorylation-sensitive T-loop essential for catalytic activity [2, 3]. Upon cyclin engagement at the PSTAIRE motif, CDKs undergo structural  \n*Correspondence:  \nShudong Wang  \n[shudong.wang@adelaide.edu.au](shudong.wang@adelaide.edu.au)  \n1Drug Discovery and Development, School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide 5001, SA, Australia  \nreorientation that exposes the T-loop threonine, allowing its phosphorylation by CDK-activating kinase (CAK)  \n[4]. Once activated, CDK–cyclin complexes interact with their substrates to regulate key cellular processes, including (i) cell cycle progression (CDK1–6), (ii) gene transcription (CDK7–13, CDK19–20), and (iii) both (CDK7, 10, 11) [4].  \nWithin this network, the CDK4/6–cyclin D complex functions as the principal conduit linking extracellular mitogenic cues to the cell cycle machinery [5]. This connection makes the activation of CDK4/6–cyclin D an Achilles’heel for cellular homeostasis. Although multiple layers of regulatory pathways control the activation of the complex, CDK4/6–cyclin D is among the most frequently dysregulated pathways in malignancy, with genetic or functional alterations detected in up to 90% of human cancers [6].  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Cre","cbCaigOqzMCuMsQc","https://ap.wps.com/l/cbCaigOqzMCuMsQc","pdf",6072044,42,"English","# Introduction\n# Therapeutic landscape of CDK4/6 inhibition\n# Selective CDK4 inhibitors and next-generation strategies\n# Conclusions","[{\"question\":\"What biological pathway does the review focus on?\",\"answer\":\"The review centers on CDK4/6–cyclin D signaling as a key link between extracellular mitogenic cues and cell-cycle control, and as a pathway frequently dysregulated in malignancy.\"},{\"question\":\"Why has CDK4/6 inhibition expanded more slowly beyond HR-positive breast cancer?\",\"answer\":\"Broader use is limited by intrinsic or acquired resistance, restricted efficacy in certain tumor contexts, and dose-limiting hematologic toxicities.\"},{\"question\":\"What is the goal behind developing next-generation selective CDK4 inhibitors?\",\"answer\":\"The intent is to overcome existing challenges by improving selectivity, refining the therapeutic window, and maintaining effective suppression of the CDK4 pathway.\"}]","Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors | PDF",1790151328,106,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60d115cda5e3a736ab222eec8fd781e1.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cdb7c30ae0c2b26e161a19f607c99d6.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95281107ce02e6908ec9242fd16fdb03.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/626da2c54cb4aa585b80ab3e358ca604.webp",980,1306,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d243f180adf6ce28339d1d94284eec11.webp",979,1305]